A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

ObjectiveTo explore the role of chidamide, decitabine plus priming regimen in the salvage treatment of relapsed/refractory acute myeloid leukemia.MethodsA clinical trial was conducted in relapsed/refractory acute myeloid leukemia patients using chidamide, decitabine, cytarabine, idarubicin, and gran...

Full description

Bibliographic Details
Main Authors: Jia Yin, Chao-Ling Wan, Ling Zhang, Hao Zhang, Lian Bai, Hai-Xia Zhou, Ming-Zhu Xu, Li-Yun Chen, Chong-Sheng Qian, Hui-Ying Qiu, Su-Ning Chen, Xiao-Wen Tang, De-Pei Wu, Yan-Ming Zhang, Ai-Ning Sun, Sheng-Li Xue
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
epigenomics
histone deacetylase inhibitor (HDACi)
CDIAG regimen
relapsed/refractory acute myeloid leukemia
salvage therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.726926/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.726926/full

Similar Items